Inhibins: From reproductive hormones to tumor suppressors

Trends in Endocrinology and Metabolism

Volumn 21, Issue 3, 2010, Pages 174-180

  Stenvers, Kaye L ^a   Findlay, Jock K ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FOLLITROPIN; INHIBIN; INHIBIN A; INHIBIN B; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

CANCER INHIBITION; CARCINOGENESIS; DIMERIZATION; GENE EXPRESSION; HORMONE ACTION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; FEMALE; HUMANS; INHIBINS; MALE; MODELS, BIOLOGICAL; NEOPLASMS; PEPTIDE HORMONES; PROTEIN ISOFORMS; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REPRODUCTION;

EID: 77949328305     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.11.009     Document Type: Review

References (68)

1. Barakat B., et al. Inhibin, activin, follistatin and FSH serum levels and testicular production are highly modulated during the first spermatogenic wave in mice. Reproduction 2008, 136:345-359.
2. Bilandzic M., et al. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol. Endocrinol. 2009, 23:539-548.
3. Bilezikjian L.M., et al. Pituitary actions of ligands of the TGF-beta family: activins and inhibins. Reproduction 2006, 132:207-215.
4. Chand A.L., et al. Functional analysis of the human inhibin alpha subunit variant A257T and its potential role in premature ovarian failure. Hum. Reprod. 2007, 22:3241-3248.
5. Chand A.L., et al. Mutational analysis of betaglycan/TGF-betaRIII in premature ovarian failure. Fertil. Steril. 2007, 87:210-212.
6. de Kretser D.M., et al. Inhibins, activins and follistatin in reproduction. Hum. Reprod. Update 2002, 8:529-541.
7. Dias V.L., et al. Analysis of activin/TGFB-signaling modulators within the normal and dysfunctional adult human testis reveals evidence of altered signaling capacity in a subset of seminomas. Reproduction 2009, 138:801-811.
8. Dixit H., et al. Mutational analysis of the betaglycan gene-coding region in susceptibility for ovarian failure. Hum. Reprod. 2006, 21:2041-2046.
9. Findlay J.K., et al. Recruitment and development of the follicle; the roles of the transforming growth factor-beta superfamily. Mol. Cell Endocrinol. 2002, 191:35-43.
10. Gaddy D. Inhibin and the regulation of bone mass. Curr. Osteoporos. Rep. 2008, 6:51-56.
11. Hamar B.D., et al. Serum and urine inhibin A but not free activin A are endocrine biomarkers of severe pre-eclampsia. Am. J. Obstet. Gynecol. 2006, 195:1636-1645.
12. Jones R.L., et al. Activin A and inhibin A differentially regulate human uterine matrix metalloproteinases: potential interactions during decidualization and trophoblast invasion. Endocrinology 2006, 147:724-732.
13. Jones R.L., et al. TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction 2006, 132:217-232.
14. Juengel J.L., McNatty K.P. The role of proteins of the transforming growth factor-beta superfamily in the intraovarian regulation of follicular development. Hum. Reprod. Update 2005, 11:143-160.
15. Knight P.G., Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction 2006, 132:191-206.
16. Kumanov P., et al. Significance of inhibin in reproductive pathophysiology and current clinical applications. Reprod. Biomed. Online 2005, 10:786-812.
17. Loveland K.L., et al. The transforming growth factor-beta superfamily in early spermatogenesis: potential relevance to testicular dysgenesis. Int. J. Androl. 2007, 30:377-384. discussion 384.
18. Luisi S., et al. Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy. Hum. Reprod. Update 2005, 11:123-135.
19. Mylonas I., et al. Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Gynecol. Oncol. 2004, 93:92-97.
20. Robertson D.M., Oehler M.K. Emerging role of inhibin as a biomarker for ovarian cancer. Womens Health (Lond. Engl.) 2005, 1:51-57.
21. Sarraj M.A., et al. Differential expression of TGFBR3 (betaglycan) in mouse ovary and testis during gonadogenesis. Growth Factors 2007, 25:334-345.
22. Tsigkou A., et al. Inhibins as diagnostic markers in human reproduction. Adv. Clin. Chem. 2008, 45:1-29.
23. Tsigkou A., et al. Total inhibin is a potential serum marker for epithelial ovarian cancer. J. Clin. Endocrinol. Metab. 2007, 92:2526-2531.
24. Woad K.J., et al. Investigating the association between inhibin alpha gene promoter polymorphisms and premature ovarian failure. Fertil. Steril. 2009, 91:62-66.
25. Matzuk M.M., et al. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992, 360:313-319.
26. Daly A.C., et al. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol. Cell Biol. 2008, 28:6889-6902.
27. Hill C.S. Nucleocytoplasmic shuttling of Smad proteins. Cell Res. 2009, 19:36-46.
28. Farnworth P.G., et al. Rodent adrenocortical cells display high affinity binding sites and proteins for inhibin A, and express components required for autocrine signalling by activins and bone morphogenetic proteins. J. Endocrinol. 2006, 188:451-465.
29. Farnworth P.G., et al. Inhibins differentially antagonize activin and bone morphogenetic protein action in a mouse adrenocortical cell line. Endocrinology 2006, 147:3462-3471.
30. Lewis K.A., et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 2000, 404:411-414.
31. Makanji Y., et al. Suppression of inhibin A biological activity by alterations in the binding site for betaglycan. J. Biol. Chem. 2008, 283:16743-16751.
32. Wiater E., Vale W. Inhibin is an antagonist of bone morphogenetic protein signaling. J. Biol. Chem. 2003, 278:7934-7941.
33. Kirkbride K.C., et al. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J. Biol. Chem. 2008, 283:7628-7637.
34. Wiater E., et al. Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. J. Biol. Chem. 2006, 281:17011-17022.
35. Escalona R.M., et al. Reducing betaglycan expression by RNA interference (RNAi) attenuates inhibin bioactivity in LbetaT2 gonadotropes. Mol. Cell Endocrinol. 2009, 307:149-156.
36. Wiater E., et al. Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes. Mol. Endocrinol. 2009, 23:1033-1042.
37. Stenvers K.L., et al. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol. Cell Biol. 2003, 23:4371-4385.
38. Florio P., et al. Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma. Eur. J. Endocrinol. 2005, 152:277-284.
39. Dong M., et al. The type III TGF-beta receptor suppresses breast cancer progression. J. Clin. Invest. 2007, 117:206-217.
40. Farnworth P.G., et al. Transforming growth factor-beta blocks inhibin binding to different target cell types in a context-dependent manner through dual mechanisms involving betaglycan. Endocrinology 2007, 148:5355-5368.
41. Drummond A.E., et al. Ovarian follicle populations of the rat express TGF-beta signalling pathways. Mol. Cell Endocrinol. 2003, 202:53-57.
42. Walton K.L., et al. A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligands. J. Biol. Chem. 2009, 284:9311-9320.
43. Antenos M., et al. An activin/furin regulatory loop modulates the processing and secretion of inhibin alpha- and betaB-subunit dimers in pituitary gonadotrope cells. J. Biol. Chem. 2008, 283:33059-33068.
44. Antenos M., et al. N-linked oligosaccharides direct the differential assembly and secretion of inhibin alpha- and betaA-subunit dimers. Mol. Endocrinol. 2007, 21:1670-1684.
45. Makanji Y., et al. Inhibin A and B in vitro bioactivities are modified by their degree of glycosylation and their affinities to betaglycan. Endocrinology 2007, 148:2309-2316.
46. Thompson T.B., et al. Beta A versus beta B: is it merely a matter of expression?. Mol. Cell Endocrinol. 2004, 225:9-17.
47. Brown C.W., et al. Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions. Nat. Genet. 2000, 25:453-457.
48. Makanji Y., et al. Inhibin B is a more potent suppressor of rat follicle-stimulating hormone release than Inhibin A in vitro and in vivo. Endocrinology 2009, 150:4784-4793.
49. Myers M., et al. Loss of inhibin alpha uncouples oocyte-granulosa cell dynamics and disrupts postnatal folliculogenesis. Dev. Biol. 2009, 334:458-467.
50. Sarraj M.A., et al. Fetal testis dysgenesis and compromised leydig cell function in Tgfbr3 (betaglycan) knockout mice. Biol. Reprod 2009, 10.1095/biolreprod.109.078766.
51. Li Q., et al. SMAD3 regulates gonadal tumorigenesis. Mol. Endocrinol. 2007, 21:2472-2486.
52. Looyenga B.D., Hammer G.D. Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery. Mol. Endocrinol. 2007, 21:2440-2457.
53. Fuller P.J., Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol. Metab. 2004, 15:122-128.
54. Balanathan P., et al. Epigenetic regulation of inhibin alpha-subunit gene in prostate cancer cell lines. J. Mol. Endocrinol. 2004, 32:55-67.
55. Balanathan P., et al. Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. Br J. Cancer 2009, 100:1784-1793.
56. Hempel N., et al. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res. 2007, 67:5231-5238.
57. Mylonas I., et al. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis. Oncol. Rep 2005, 13:81-88.
58. Mylonas I., et al. Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur. J. Cancer 2009, 45:1304-1314.
59. Sharifi N., et al. TGFBR3 loss and consequences in prostate cancer. Prostate 2007, 67:301-311.
60. Turley R.S., et al. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007, 67:1090-1098.
61. Steller M.D., et al. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol. Cancer Res. 2005, 3:50-61.
62. Bierie B., Moses H.L. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 2009, 8:3319-3327.
63. Simon D.P., et al. Activin receptor signaling regulates prostatic epithelial cell adhesion and viability. Neoplasia 2009, 11:365-376.
64. Criswell T.L., Arteaga C.L. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. J. Biol. Chem. 2007, 282:32491-32500.
65. Criswell T.L., et al. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res. 2008, 68:7304-7312.
66. Finger E.C., et al. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 2008, 29:528-535.
67. Gordon K.J., et al. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 2008, 29:252-262.
68. Mythreye K., Blobe G.C. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8221-8226.